- CNE/CME QUESTIONS. // AIDS Alert;May2010, Vol. 25 Issue 5, p59
A quiz is presented related to medical care for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) patients.
- Most Pharmaceutical Companies Receive Poor Grades on HIV/AIDS Drug Development Innovation, According to AIDS Treatment Activist Coalition Report Card; Many Companies Get Low Marks in Five Benchmark Treatment Categories; New Drugs Need to Reflect... // Ascribe Newswire: Health;9/10/2009, p1
The article reports on the poor grades received by most U.S. pharmaceutical companies on HIV and AIDS drug development innovation. According to AIDS Treatment Activist Coalition Report Card, most companies obtain low marks in five benchmark treatment categories. It indicates that many...
- New Therapies in HIV/AIDS Treatment. Garmany, Justin; Kramer, Richard // Drug Formulary Review;Jun2008 Supplement, Vol. 24, p1
The article focuses on the developments in therapies for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). It emphasizes the positive effect of highly reactive antiretro-viral therapy (HAART) on the quality of life, T cell count and survival in HIV patients. The...
- Targeting Divalent Metal Ions at the Active Site of the HIV-1 RNase H Domain: NMR Studies on the Interactions of Divalent Metal Ions with RNase H and Its Inhibitors. Jiangli Yan; Haihong Wu; Tom, Tiffany; Brodsky, Oleg; Maegley, Karen // American Journal of Analytical Chemistry;Oct2011, Vol. 2 Issue 6, p639
HIV-1 reverse transcriptase (RT) RNase H (HIV-RH) is a key target of anti-AIDS drugs. Metal-chelating compounds are an important class of chemicals in pharmacological drug discovery, especially in relation to HIV-RT and the highly-related HIV-integrase. The correlation between the...
- HIV Antiretroviral Drug Resistance. Campo, Jose E.; Jamjian, Christine; Goulston, Claudia // Journal of AIDS & Clinical Research;Special2012, Vol. 3 Issue S, Special section p1
The article describes some of the challenges in the use of highly active antiretroviral therapy (HAART) from the perspective of HIV resistance. It defines drug resistance in HIV as a reduced susceptibility to a specific antiretroviral (ARV) and has been documented since the introduction of ARV...
- Effect of Immunization with a Common Recall Antigen on Viral Expression in Patients Infected with Human Immunodeficiency Virus Type 1. // New England Journal of Medicine;8/22/96, Vol. 335 Issue 8, p607
A correction to the article "Effect of Immunization with a Common Recall Antigen on Viral Expression in Patients Infected with Human Immunodeficiency Virus Type 1" that was published in the May 9, 1996 issue is presented.
- Adherence can cause increase in direct ART and health care costs. // AIDS Alert;Apr2009, Vol. 24 Issue 4, p41
The article reports that high adherence to antiretroviral treatment (ART) use can cause increase in health care costs in treating patients with HIV.
- CNE/CME questions. // AIDS Alert;Dec2009, Vol. 24 Issue 12, p143
No abstract available.
- HIV clinic gets ART to toughest cases. // AIDS Alert;May2010, Vol. 25 Issue 5, p51
The article focuses on the launch of a health program which provides medication therapy support to human immunodeficiency virus (HIV) patients in January 2009 in Nashville, Tennessee.